Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.14
+0.03 (0.18%)
At close: Aug 13, 2025, 4:00 PM
17.48
+0.34 (1.98%)
After-hours: Aug 13, 2025, 4:43 PM EDT
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 77 employees as of December 31, 2024. The number of employees increased by 1 or 1.32% compared to the previous year.
Employees
77
Change (1Y)
1
Growth (1Y)
1.32%
Revenue / Employee
$194,805
Profits / Employee
-$2,991,857
Market Cap
2.30B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77 | 1 | 1.32% |
| Dec 31, 2023 | 76 | -7 | -8.43% |
| Dec 31, 2022 | 83 | -7 | -7.78% |
| Dec 31, 2021 | 90 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CNTA News
- 1 day ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - GlobeNewsWire
- 5 weeks ago - Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting - GlobeNewsWire
- 7 months ago - Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer - GlobeNewsWire